September 23, 2026

Otsuka and Ionis report positive data in Phase III FUSION trial of ulefnersen

​Otsuka Pharmaceutical Development & Commercialization, Otsuka Pharmaceutical, and Ionis Pharmaceuticals have reported encouraging top-line data from the Phase III FUSION...

September 23, 2026

QC Healthcare and Sanguina collaborate for AI blood health tools

​QC Healthcare has entered into a collaboration with Sanguina to implement AI-based blood health technologies across its digital healthcare platforms...

September 23, 2026

Boehringer and Envisagenics to develop precision cancer therapies

​Boehringer Ingelheim and Envisagenics have entered into a research collaboration and option agreement aimed at validating tumour-specific targets for the...

September 22, 2026

FDA approves Cordis SELUTION SLR for coronary in-stent restenosis

​The US FDA has approved Cordis’ SELUTION SLR [sustained limus release] DEB to treat coronary in-stent restenosis (ISR).The post FDA...

September 22, 2026

Alkermes reports positive top-line Phase Ib trial data for ALKS 7290

​Alkermes has reported positive top-line findings from a Phase Ib proof-of-concept study of ALKS 7290 for adults with ADHD.The post...

September 22, 2026

EC approves Menarini and NewAmsterdam’s obicetrapib therapies

​The EC has granted marketing authorisation to NewAmsterdam Pharma and Menarini Group for Ubeslo and Evlarco.The post EC approves Menarini...

September 21, 2026

CardiaCare secures seed extension funding for AFib clinical studies

​CardiaCare has closed an oversubscribed seed extension funding round to support clinical pilot studies of its wearable technology for cardiac...

September 21, 2026

Otsuka reports expanded Phase IIIb results for Simtriyo in adult ADHD

​Otsuka Pharmaceutical Development & Commercialisation and Otsuka Pharmaceutical have reported expanded Phase IIIb results for Simtriyo in adults with ADHD...

September 21, 2026

Sandoz and mAbxience agree on emicizumab biosimilar partnership

​Sandoz and mAbxience have signed a licensing, development and commercialisation agreement for a proposed emicizumab biosimilar candidate for haemophilia A.The...

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.